BR112012006957A2 - regime de dosagem de um modulador de receptor de s1p - Google Patents

regime de dosagem de um modulador de receptor de s1p

Info

Publication number
BR112012006957A2
BR112012006957A2 BR112012006957A BR112012006957A BR112012006957A2 BR 112012006957 A2 BR112012006957 A2 BR 112012006957A2 BR 112012006957 A BR112012006957 A BR 112012006957A BR 112012006957 A BR112012006957 A BR 112012006957A BR 112012006957 A2 BR112012006957 A2 BR 112012006957A2
Authority
BR
Brazil
Prior art keywords
dosing regimen
receptor modulator
modulator
receptor
regimen
Prior art date
Application number
BR112012006957A
Other languages
English (en)
Inventor
Ana De Vera
Craig Boulton
Irene Hunt
Olivier David
Pascale Burtin
Robert Schmouder
Thomas Dumortier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012006957(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012006957A2 publication Critical patent/BR112012006957A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
BR112012006957A 2009-09-29 2010-09-20 regime de dosagem de um modulador de receptor de s1p BR112012006957A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24670609P 2009-09-29 2009-09-29
US25832909P 2009-11-05 2009-11-05
US30799210P 2010-02-25 2010-02-25
US35202910P 2010-06-07 2010-06-07
PCT/US2010/049441 WO2011041146A2 (en) 2009-09-29 2010-09-20 Dosage regimen of an s1p receptor modulator

Publications (1)

Publication Number Publication Date
BR112012006957A2 true BR112012006957A2 (pt) 2016-06-14

Family

ID=43759693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006957A BR112012006957A2 (pt) 2009-09-29 2010-09-20 regime de dosagem de um modulador de receptor de s1p

Country Status (18)

Country Link
US (8) US20120264719A1 (pt)
EP (4) EP2482810A2 (pt)
JP (5) JP2013505983A (pt)
KR (1) KR20120083442A (pt)
CN (2) CN103933570A (pt)
AU (2) AU2010101513B4 (pt)
BR (1) BR112012006957A2 (pt)
CA (2) CA2773330C (pt)
IL (2) IL218486A0 (pt)
MA (1) MA33691B1 (pt)
MX (1) MX2012003740A (pt)
NZ (1) NZ598534A (pt)
PH (1) PH12017501495A1 (pt)
RU (1) RU2012117563A (pt)
SG (4) SG10201406168RA (pt)
TN (1) TN2012000104A1 (pt)
WO (1) WO2011041146A2 (pt)
ZA (2) ZA201201678B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041146A2 (en) * 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
WO2013057212A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
CA2900844C (en) * 2013-04-04 2022-05-03 Novartis Ag Identifying patient response to s1p receptor modulator administration
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
SG11202111417UA (en) * 2019-04-17 2021-11-29 Pear Therapeutics Inc Electronic devices and methods for treatment of depressive symptoms, depressive disorders utilizing digital therapies
WO2021158847A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158844A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2021158841A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158843A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158845A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158839A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231560B1 (en) * 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
CN1652757B (zh) 2002-05-16 2012-02-08 诺瓦提斯公司 Edg受体结合剂在癌症中的应用
GB0211261D0 (en) * 2002-05-16 2002-06-26 Novartis Ag Organic compounds
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
JP4728962B2 (ja) 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
SG158096A1 (en) 2004-11-29 2010-01-29 Novartis Ag Dosage regimen of an s1p receptor agonist
JP2007061274A (ja) * 2005-08-30 2007-03-15 Transcutaneous Technologies Inc センサからの副作用情報による投薬停止システムを備えたイオントフォレーシス装置
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
WO2009155475A1 (en) 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
EP4098256A1 (en) 2008-12-22 2022-12-07 Novartis AG Dosage regimen for a s1p receptor agonist
WO2011041146A2 (en) * 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator

Also Published As

Publication number Publication date
IL250439A0 (en) 2017-03-30
EP3047848A1 (en) 2016-07-27
US20120264719A1 (en) 2012-10-18
JP2013505983A (ja) 2013-02-21
MA33691B1 (fr) 2012-10-01
JP2016155840A (ja) 2016-09-01
AU2010300919A1 (en) 2012-03-22
RU2018118645A3 (pt) 2021-09-13
JP2020203892A (ja) 2020-12-24
SG10201406168RA (en) 2014-11-27
PH12017501495A1 (en) 2018-07-02
US20180263929A1 (en) 2018-09-20
IL218486A0 (en) 2012-04-30
EP2482810A2 (en) 2012-08-08
ZA201404270B (en) 2014-12-23
TN2012000104A1 (en) 2013-09-19
CN102548579A (zh) 2012-07-04
MX2012003740A (es) 2012-04-30
WO2011041146A3 (en) 2011-06-03
RU2012117563A (ru) 2013-11-10
SG10201902152XA (en) 2019-04-29
AU2010101513B4 (en) 2016-05-05
NZ598534A (en) 2014-03-28
CN103933570A (zh) 2014-07-23
US20170304226A1 (en) 2017-10-26
SG10201913361RA (en) 2020-03-30
JP2023093482A (ja) 2023-07-04
SG178987A1 (en) 2012-04-27
US10543179B2 (en) 2020-01-28
US20180263930A1 (en) 2018-09-20
US20230086687A1 (en) 2023-03-23
EP3831371A1 (en) 2021-06-09
AU2010101513A4 (en) 2014-06-26
JP7185426B2 (ja) 2022-12-07
KR20120083442A (ko) 2012-07-25
RU2018118645A (ru) 2018-11-05
CA2773330A1 (en) 2011-04-07
AU2010101513A6 (en) 2014-07-10
US20200222338A1 (en) 2020-07-16
US20140187516A1 (en) 2014-07-03
US11759436B2 (en) 2023-09-19
JP2018172401A (ja) 2018-11-08
ZA201201678B (en) 2016-01-27
CA2773330C (en) 2021-11-02
US20160256416A1 (en) 2016-09-08
EP3061449A1 (en) 2016-08-31
CA3129729A1 (en) 2011-04-07
WO2011041146A2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
BR112012006957A2 (pt) regime de dosagem de um modulador de receptor de s1p
CY2020014I2 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
DK2358686T3 (da) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
DK2382135T3 (da) Emballagestruktur af beholdere til farmaceutisk anvendelse
BR112013020035A2 (pt) moduladores do receptor do glucagon
BR112013015260A2 (pt) derivados de enxofre como moduladores de receptor de quimiocina
HK1208225A1 (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1
DK3385252T3 (da) Cannabinoidreceptormodulatorer
EP2624697A4 (en) POSITIVE ALLOSTERIC DIHYDROBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS
BR112013033777A2 (pt) moduladores de receptor de hormônio nuclear
CO6900143A2 (es) Derivados de étinilo como moduladores alostéricos de mglur5
EP2709451A4 (en) POSITIVE ALLOSTERIC N-NETWORKED LACTAM M1 RECEPTOR MODULATORS
EP2709621A4 (en) POSITIVE ALLOSERIC MODULATORS OF M1 RECEPTOR TO QUINOLINE-AMIDE N-BINDING
BRPI0913913A2 (pt) regime de dosagem para nitrocatecóis
BR112013016033A2 (pt) moduladores do receptor de glucagon
BR112013013643A2 (pt) derivados de oxadiazol como moduladores de receptor de esfingosina-1-fosfato (s1p)
BR112013013639A2 (pt) derivados de azetidina como moduladores do receptor de esfingosina-1-fosfato (s1p)
ZA201402283B (en) Dosage regimen for an s1p receptor modulator or agonist
BR112013013640A2 (pt) derivados de oxima como moduladores de receptores de esfingosina-1-fosfato (s1p)
EP2796459A4 (en) NEW S1P RECEIVER MODULATOR
EP2809156A4 (en) 5-HYDROXYTRYPTAMINE (5HT2CR) 2C RECEPTOR 2C ALLOSTERIC MODULATORS
NO20100146A1 (no) Anordning for væskedosering
BR112013013645A2 (pt) derivados de alqueno como moduladores de receptores de esfingosina-1-fosfato (s1p)
FR2967206B1 (fr) Distributeur pour turbomoteur

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]